Free Trial

Pharvaris (PHVS) Competitors

Pharvaris logo
$23.39 +0.21 (+0.91%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$23.44 +0.04 (+0.19%)
As of 10/3/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PHVS vs. KRYS, PTCT, MENS, ARWR, ACLX, PCVX, CRNX, PTGX, KYMR, and MLTX

Should you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Jyong Biotech (MENS), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Vaxcyte (PCVX), Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

Pharvaris vs. Its Competitors

Pharvaris (NASDAQ:PHVS) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Pharvaris has a beta of -2.77, indicating that its share price is 377% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Krystal Biotech has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PharvarisN/AN/A-$145.24M-$3.36-6.96
Krystal Biotech$290.52M18.27$89.16M$4.9237.27

In the previous week, Krystal Biotech had 2 more articles in the media than Pharvaris. MarketBeat recorded 4 mentions for Krystal Biotech and 2 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.25 beat Krystal Biotech's score of 1.21 indicating that Pharvaris is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharvaris
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Krystal Biotech
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pharvaris currently has a consensus target price of $34.00, indicating a potential upside of 45.36%. Krystal Biotech has a consensus target price of $209.00, indicating a potential upside of 13.98%. Given Pharvaris' higher possible upside, equities analysts plainly believe Pharvaris is more favorable than Krystal Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharvaris
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Krystal Biotech
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75

Krystal Biotech has a net margin of 40.85% compared to Pharvaris' net margin of 0.00%. Krystal Biotech's return on equity of 15.21% beat Pharvaris' return on equity.

Company Net Margins Return on Equity Return on Assets
PharvarisN/A -69.09% -63.34%
Krystal Biotech 40.85%15.21%13.81%

86.3% of Krystal Biotech shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 13.7% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Krystal Biotech beats Pharvaris on 13 of the 15 factors compared between the two stocks.

Get Pharvaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHVS vs. The Competition

MetricPharvarisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.22B$3.36B$6.13B$10.58B
Dividend YieldN/A2.28%5.65%4.69%
P/E Ratio-6.9622.2886.9626.71
Price / SalesN/A458.33604.82131.77
Price / CashN/A47.8637.9061.31
Price / Book4.229.9312.556.55
Net Income-$145.24M-$52.80M$3.31B$277.50M
7 Day Performance-3.23%5.22%4.28%2.42%
1 Month Performance1.48%10.61%6.90%8.63%
1 Year Performance28.52%25.03%70.54%31.60%

Pharvaris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHVS
Pharvaris
2.2907 of 5 stars
$23.39
+0.9%
$34.00
+45.4%
+28.5%$1.22BN/A-6.9630Positive News
Gap Down
KRYS
Krystal Biotech
4.6773 of 5 stars
$176.75
+5.3%
$209.00
+18.2%
+3.5%$4.86B$290.52M35.92210Positive News
PTCT
PTC Therapeutics
3.4237 of 5 stars
$60.65
+2.8%
$69.00
+13.8%
+86.2%$4.69B$806.78M8.701,410
MENS
Jyong Biotech
N/A$50.00
-16.3%
N/AN/A$4.54BN/A0.0031
ARWR
Arrowhead Pharmaceuticals
4.1691 of 5 stars
$33.78
+3.0%
$43.14
+27.7%
+91.9%$4.53B$572.98M-26.39400Insider Trade
ACLX
Arcellx
2.2263 of 5 stars
$79.11
-0.8%
$114.31
+44.5%
+8.7%$4.42B$56.98M-23.1380Insider Trade
PCVX
Vaxcyte
2.4646 of 5 stars
$34.65
+2.0%
$106.25
+206.6%
-61.7%$4.41BN/A-8.43160Positive News
CRNX
Crinetics Pharmaceuticals
3.9309 of 5 stars
$43.51
-5.2%
$73.20
+68.2%
-23.1%$4.32B$1.04M-10.59210Analyst Forecast
Insider Trade
PTGX
Protagonist Therapeutics
2.1551 of 5 stars
$65.14
-3.4%
$68.36
+4.9%
+46.1%$4.19B$434.43M93.06120Positive News
KYMR
Kymera Therapeutics
1.9279 of 5 stars
$58.50
+4.0%
$59.95
+2.5%
+34.5%$4.02B$47.07M-16.86170Analyst Forecast
MLTX
MoonLake Immunotherapeutics
2.9744 of 5 stars
$6.24
-89.9%
$57.00
+813.5%
-84.8%$3.98BN/A-2.242Trending News
Analyst Forecast
Insider Trade
Analyst Revision
High Trading Volume

Related Companies and Tools


This page (NASDAQ:PHVS) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners